These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36252167)

  • 1. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
    You B; Purdy C; Copeland LJ; Swisher EM; Bookman MA; Fleming G; Coleman R; Randall LM; Tewari KS; Monk BJ; Mannel RS; Walker JL; Cappuccini F; Cohn D; Muzaffar M; Mutch D; Wahner-Hendrickson A; Martin L; Colomban O; Burger RA
    J Clin Oncol; 2022 Dec; 40(34):3965-3974. PubMed ID: 36252167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial.
    Colomban O; Clamp A; Cook A; McNeish IA; You B
    JCO Clin Cancer Inform; 2023 Apr; 7():e2200188. PubMed ID: 37075255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
    You B; Sehgal V; Hosmane B; Huang X; Ansell PJ; Dinh MH; Bell-McGuinn K; Luo X; Fleming GF; Friedlander M; Bookman MA; Moore KN; Steffensen KD; Coleman RL; Swisher EM
    J Clin Oncol; 2023 Jan; 41(1):107-116. PubMed ID: 35867965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".
    van Wagensveld L; Colomban O; van der Aa MA; Freyer G; Sonke GS; Kruitwagen RFPM; You B
    J Gynecol Oncol; 2024 May; 35(3):e34. PubMed ID: 38216134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.
    Colomban O; Tod M; Leary A; Ray-Coquard I; Lortholary A; Hardy-Bessard AC; Pfisterer J; Du Bois A; Kurzeder C; Burges A; Péron J; Freyer G; You B
    Clin Cancer Res; 2019 Sep; 25(17):5342-5350. PubMed ID: 30936122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
    You B; Robelin P; Tod M; Louvet C; Lotz JP; Abadie-Lacourtoisie S; Fabbro M; Desauw C; Bonichon-Lamichhane N; Kurtz JE; Follana P; Leheurteur M; Piano FD; Ferron G; De Rauglaudre G; Ray-Coquard I; Combe P; Chevalier-Place A; Joly F; Leary A; Pujade-Lauraine E; Freyer G; Colomban O
    Clin Cancer Res; 2020 Sep; 26(17):4625-4632. PubMed ID: 32209570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7).
    Colomban O; Tod M; Peron J; Perren TJ; Leary A; Cook AD; Sajous C; Freyer G; You B
    JNCI Cancer Spectr; 2020 Jun; 4(3):pkaa026. PubMed ID: 32596636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma.
    Piedimonte S; Murray C; Atenafu EG; Rouzbahman M; Lheureux S; May T
    Gynecol Oncol; 2024 Aug; 187():92-97. PubMed ID: 38735145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
    Corbaux P; You B; Glasspool RM; Yanaihara N; Tinker AV; Lindemann K; Ray-Coquard IL; Mirza MR; Subtil F; Colomban O; Péron J; Karamouza E; McNeish I; Kelly C; Kagimura T; Welch S; Lewsley LA; Paoletti X; Cook A
    Eur J Cancer; 2023 Sep; 191():112966. PubMed ID: 37542936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
    Alvarez Secord A; Bell Burdett K; Owzar K; Tritchler D; Sibley AB; Liu Y; Starr MD; Brady JC; Lankes HA; Hurwitz HI; Mannel RS; Tewari KS; O'Malley DM; Gray H; Bakkum-Gamez JN; Fujiwara K; Boente M; Deng W; Burger RA; Birrer MJ; Nixon AB
    Clin Cancer Res; 2020 Mar; 26(6):1288-1296. PubMed ID: 31919136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA.
    Carrot A; Oudard S; Colomban O; Fizazi K; Maillet D; Sartor O; Freyer G; You B
    JCO Clin Cancer Inform; 2024 Feb; 8():e2300208. PubMed ID: 38364191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals.
    Li C; Cui Q; Wang X; Yao S; Tu H; Chen M
    BMC Cancer; 2024 May; 24(1):609. PubMed ID: 38769484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients.
    Bouvarel B; Colomban O; Frenel JS; Loaec C; Bourgin C; Berton D; Freyer G; You B; Classe JM
    Int J Gynecol Cancer; 2024 Apr; 34(4):574-580. PubMed ID: 38242546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study).
    You B; Colomban O; Heywood M; Lee C; Davy M; Reed N; Pignata S; Varsellona N; Emons G; Rehman K; Steffensen KD; Reinthaller A; Pujade-Lauraine E; Oza A
    Gynecol Oncol; 2013 Aug; 130(2):289-94. PubMed ID: 23694718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer.
    Kus F; Guven DC; Yildirim HC; Chalabiyev E; Akyildiz A; Tatar OD; Sahin YB; Ileri S; Karaca E; Kertmen N; Arik Z
    Biomark Med; 2023 Apr; 17(7):379-389. PubMed ID: 37309756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External validation of Standardized KELIM and platinum-resistant recurrence scores in patients with advanced epithelial ovarian cancer.
    Oufkir N; Rouzier R; Paoletti X; Bonneau C
    J Ovarian Res; 2024 Jul; 17(1):152. PubMed ID: 39039554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10.
    Colomban O; Swisher EM; Kristeleit R; McNeish I; Shapira-Frommer R; Goble S; Lin KK; Maloney L; Freyer G; You B
    EBioMedicine; 2023 Mar; 89():104477. PubMed ID: 36801617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
    Gore M; Hackshaw A; Brady WE; Penson RT; Zaino R; McCluggage WG; Ganesan R; Wilkinson N; Perren T; Montes A; Summers J; Lord R; Dark G; Rustin G; Mackean M; Reed N; Kehoe S; Frumovitz M; Christensen H; Feeney A; Ledermann J; Gershenson DM
    Gynecol Oncol; 2019 Jun; 153(3):541-548. PubMed ID: 31005287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
    Tewari KS; Burger RA; Enserro D; Norquist BM; Swisher EM; Brady MF; Bookman MA; Fleming GF; Huang H; Homesley HD; Fowler JM; Greer BE; Boente M; Liang SX; Ye C; Bais C; Randall LM; Chan JK; Ferriss JS; Coleman RL; Aghajanian C; Herzog TJ; DiSaia PJ; Copeland LJ; Mannel RS; Birrer MJ; Monk BJ
    J Clin Oncol; 2019 Sep; 37(26):2317-2328. PubMed ID: 31216226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer.
    Piedimonte S; Kim R; Bernardini MQ; Atenafu EG; Clark M; Lheureux S; May T
    Gynecol Oncol; 2022 Dec; 167(3):417-422. PubMed ID: 37191644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.